Patients who suffer an adverse medical event arising from the use or misuse of medications are more costly to the health care system than other emergency department (ED) patients, say physicians and research scientists at Vancouver General Hospital and UBC. Their research, the first to examine the health outcomes and cost of patient care for patients presenting to the ED with adverse drug events, is published today in the Annals of Emergency Medicine.
The research team, led by Dr. Corinne Hohl, emergency physician at Vancouver General Hospital and research scientist with the Centre for Clinical Epidemiology and Evaluation at Vancouver Coastal Health and the University of British Columbia, studied the health outcomes of patients who had presented to the emergency department with an adverse drug event and compared them to patients who presented for other reasons.
An adverse drug event is an unwanted and unintended medical event related to the use of medications.
After adjustment for baseline differences between patient groups, researchers found no difference in the mortality rate of the patients they studied, but those presenting with an adverse drug event had a 50% greater risk of spending additional days in hospital, as well as a 20 % higher rate of outpatient health care needs. The team followed 1,000 emergency department patients from Vancouver General Hospital for six months.
This new research builds on a 2008 study, published in the Canadian Medical Journal, which showed more than one in nine emergency department visits are due to medication-related problems.
"What we are finding is that these incidents are common and costly, both in terms of patient health and utilization of health care dollars," says Dr. Corinne Hohl. "We also know that these events are hard for physicians to recognize, and that nearly 70 percent of these incidents are preventable."
In BC alone, hospital emergency departments treat an estimated 210,000 patients each year for adverse drug events. The most common reasons for them are adverse drug reactions or side effects to medication, non adherence, and the wrong or suboptimal use of medication. The research team estimates that the cost of treating these patients is 90% greater than the cost of treating other patients after adjustment for differences in baseline characteristics. The added cost could be as much as $49 million annually.
The research team has been developing screening tools to better assist health care providers in the emergency department in recognizing patients at high risk for adverse drug events, as well as developing an evaluation platform that will help inform prescribing practices for physicians in the community
"We anticipate the development of a screening tool will be able to increase the recognition rate of these adverse drug events from 60 to over 90 percent, and we will be able to treat the patient effectively and rapidly, improving his or her care," says Dr. Hohl.
"Right now we spend a lot of time trying to diagnose what is wrong with the patient, yet often miss the fact that there is a medication-related problem. This means that patients often go home still on a medication which may be causing harm." We are also using the data from this research project to help develop a new drug evaluation platform to inform prescribing practices for physicians in the community. The hope is to prevent many of these adverse events from even taking place."
Funding support for this research is through Vancouver Coastal Health Research Institute, the Michael Smith Foundation for Health Research, and the Department of Surgery at the University of British Columbia.
Brian Lin | EurekAlert!
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences